Fakeeh Care Group Reports Record Quarterly Revenue of SAR 931 million, Up 20% Year on Year, as Patients Served Rise 24%; New Business Turns EBITDA Positive for the First Time and Now Generates 29% of Group Revenue

The Group consolidates Dr. Mohammed Al Fagih Hospital (DMFH) in Riyadh, opens new medical centers in Makkah and Jeddah, and holds more than 340 built beds to drive its next phase of growth

3Q-2026 Highlights[1]

Revenue
SAR 931 MN
▲ 20% YoY

Gross Profit
SAR 202 MN
▲ 14% YoY / 22% margin

Total Patients Served[2]
592,977
▲ 24% YoY

EBITDA[3]
SAR 138 MN
▲ 10% YoY / 15% margin

Attributable Net Profit
SAR 39 MN
▼ 46% YoY

Earnings Per Share
SAR 0.17
▼ 46% YoY

New Business Revenue[4]
SAR 272 MN
▲ 212% YoY

New Business Patients[2]
208,673
▲ 216% YoY

9M-2026 Highlights[1]

Revenue
SAR 2,454 MN
▲ 7% YoY

Gross Profit
SAR 517 MN
▼ 3% YoY / 21% margin

Total Patients Served[2]
1,517,285
▲ 10% YoY

EBITDA[3]
SAR 357 MN
▼ 5% YoY / 15% margin

Attributable Net Profit
SAR 135 MN
▼ 40% YoY

Earnings Per Share
SAR 0.59
▼ 40% YoY

New Business Revenue[4]
SAR 510 MN
▲ 137% YoY

New Business Patients[2]
373,039
▲ 126% YoY

Jeddah, KSA, 05 November 2026: Dr Soliman Abdel Kader Fakeeh Hospital Company and its Subsidiaries ("Fakeeh Care Group", "FCG", "Fakeeh Care", the "Company" or the "Group"), a leading fully integrated academic healthcare provider listed on TASI (SYMBOL: 4017 and ISIN code SA562GSHUOH7), announces today its financial results[1] for the period ended 30 September 2026.

Key Financial & Operational Highlights

- **Highest Quarterly Revenue in the Group's History:** Group revenue rose 20% to SAR 931 million in 3Q26 and 7% to SAR 2,454 million in 9M26. The New Business led this growth, more than tripling its revenue to SAR 272 million in 3Q26 and accounting for 29% of Group revenue, up from 11% in 3Q25, as DMFH joined the Group in July and DSFH Riyadh and DSFH Madinah continued to scale. Excluding DMFH, Group revenue grew 5% in 3Q26 and 2% in 9M26.

[1] *In accordance with the International Financial Reporting Standards (IFRS).*
[2] *The Group calculates Patients Served as the total of outpatients, inpatients, and home healthcare cases served during the period.*
[3] *The Group calculates EBITDA as Earnings Before Interest and Tax (EBIT) plus depreciation and amortization, and non-cash Long-term Incentive Plan (LTIP).*
[4] *The Group presents New Business performance as the combined financial and operational figures of DSFH Riyadh, DSFH Madinah, DMFH (from July 2026), DSFMC Al Awali and DSFMC North Obhur.*

- **Patient Growth Led by Complex Care:** Growth in patients served drove the increase in revenue. The Group served 592,977 patients in 3Q26, up 24%, and 1,517,285 in 9M26, up 10%, while inpatient admissions and surgical procedures each rose 54% in 3Q26. Excluding DMFH, patients served grew 3% in 3Q26, while inpatient admissions grew 17% and surgical procedures 22%, confirming the continued case mix optimization toward complex care.

- **More Than 340 Built Beds to Support Future Growth:** The Group operated 763 beds at the end of 3Q26, up from 526 a year earlier. As the New Business continues to ramp up, the Group has more than 340 further beds to commission over the coming years across DSFH Riyadh, DSFH Madinah and DMFH. These beds can be brought into service without significant further capital expenditure, whereby the Group will commission them in step with demand and its ability to staff them.

- **Record Quarterly Gross Profit:** Revenue growth carried through to gross profit, which reached SAR 202 million in 3Q26, the highest quarterly gross profit in the Group's history and 14% above 3Q25. The New Business drove the improvement, turning a gross loss in 3Q25 into a gross profit in 3Q26.

- **EBITDA Up 10% as the New Business Turns Positive:** EBITDA rose 10% from 3Q25 to SAR 138 million in 3Q26, at a 14.8% margin, and reached SAR 357 million in 9M26. For the first time, the New Business recorded positive EBITDA, at SAR 6 million against a loss of SAR 30 million in 3Q25. DSFH Riyadh and DSFH Madinah turned EBITDA positive on a combined basis and, together with DMFH, allowed the segment to absorb the opening costs of the two new medical centers. The Mature Business and ancillary businesses continue to hold their EBITDA margin of c.20% in each quarter of 2026.

- **Net Profit Reflects the Costs Associated with the DMFH Investment:** Below EBITDA, 3Q26 was the first quarter to carry the depreciation and financing costs of the DMFH acquisition. Although DSFH Riyadh and DSFH Madinah more than halved their combined net loss in 3Q26, net profit was SAR 38 million in 3Q26 (3Q25: SAR 57 million) and SAR 118 million in 9M26 (9M25: SAR 193 million). Profit attributable to shareholders was SAR 39 million in 3Q26 and SAR 135 million in 9M26, with earnings per share of SAR 0.17 and SAR 0.59.

- **DMFH Acquisition Funded Through Bank Debt, With Deleveraging a Priority:** The SAR 1.6 billion acquisition was funded through credit facilities from local banks, with no new shares issued. Net debt stood at SAR 2,241 million at the end of 3Q26, 0.61 times total equity and 4.1 times LTM EBITDA on a pro forma basis[1]. Total liquid funds of SAR 737 million, back at their December 2025 level, support the balance sheet, and EBITDA growth as built capacity ramps up is expected to drive deleveraging.

- **Hub-and-Spoke Network Expands Across Three Cities:** With DMFH joining in July, the Group now operates two hospitals in Riyadh. Its network of medical centers also grew: DSFMC Al Awali began receiving patients in Makkah in 3Q26, and DSFMC North Obhur opened in north Jeddah in 4Q26.

- **Five DSFH Jeddah Specialties Ranked Among the World's Best:** DSFH Jeddah entered Newsweek's World's Best Specialized Hospitals 2027 ranking with five specialties. It ranked first among all Saudi hospitals in nephrology, gastroenterology and pulmonology, and first among private hospitals in urology.

- **Advancing Robotic and Complex Care:** DSFH Jeddah performed Saudi Arabia's first robotic transoral thyroidectomies, completed a robotic esophagectomy for gastroesophageal cancer, and carried out its first ROSA-assisted knee replacement. The Global Sepsis Alliance also selected it as a Founding Pilot Partner for a new global accreditation framework for sepsis care.

[1] *Pro forma LTM EBITDA includes DMFH's EBITDA for the full twelve months, as explained under Balance Sheet, Liquidity & Capital Deployment.*

Commenting on the Group's performance, FCG's President Dr. Mazen Soliman Fakeeh said:

"When we listed on the Saudi Stock Exchange (Tadawul) in 2024, we set out to grow Fakeeh Care Group from a Jeddah based institution into a national healthcare network. This quarter shows that plan taking shape. We served nearly 593,000 patients, 24% more than a year ago, and revenue reached SAR 931 million, the highest in our history, 20% above last year and drawn from a more diversified base.

Growth on this scale comes with costs, and this quarter's results reflect them. Profit attributable to shareholders fell as we carried the first depreciation and financing costs of the Dr. Mohammed Al Fagih Hospital acquisition (DMFH), and as our Jeddah business operated in a more competitive market. Our priority now is to convert the platform we have built into sustainable profitability and cash generation.

There are clear signs of progress. Our New Business passed an important threshold this quarter. A year ago, it contributed just over a tenth of Group revenue. Today it generates 29%, and for the first time it is EBITDA positive. DSFH Riyadh and DSFH Madinah have together moved from a loss to a positive EBITDA and, with DMFH, more than absorbed the costs of opening two new medical centers. Our newer hospitals can now help carry our growth strategy, rather than relying solely on the Mature Business.

We continue to deliver on our expansion plan. A year ago, we operated 526 beds within a built capacity of 785. Today, with DMFH in the Group, we operate 763 beds within a built capacity of 1,135, across Jeddah, Riyadh, and Madinah. DSFMC Al Awali in Makkah and DSFMC North Obhur in Jeddah are now open, DSFMC Al Zahra will follow in 1Q27, and the rest of our growth pipeline is progressing well. Our expansion has given us more than 340 additional built beds across Riyadh and Madinah. We will bring them into service in step with demand and our ability to staff them well, and we will judge every new bed, clinic and investment by the return it earns on the capital we commit.

In Jeddah, where competition has increased, we are doing more of what we have always done best. DSFH Jeddah has long been one of the Kingdom's leading providers of complex care, and a growing share of its capacity continues to be dedicated to it. Newsweek has ranked five of its specialties among the best in the world, three of them first in the Kingdom, and our surgeons recently performed the country's first robotic transoral thyroidectomies. Alongside this, automation, operational efficiency and shorter patient stays are helping us care for more patients with the beds we have.

Behind these figures are more patients across the Kingdom receiving advanced care closer to home. Our integrated model, which spans the entire spectrum of healthcare delivery, was designed with value-based care at its core. We will keep investing in the clinical innovation and digital infrastructure that lead to better outcomes for our patients. Better outcomes for patients and sustainable returns for our shareholders go hand in hand. We will keep firm control of our costs and enable the cash our hospitals generate to strengthen our balance sheet as we progress.

I would like to thank our physicians, nurses and colleagues, whose dedication made this quarter possible, our patients for the trust they place in us, and our shareholders and partners for their continued support."

Strategic Developments

- **Five DSFH Jeddah Specialties Ranked Among the World's Best by Newsweek**
  DSFH Jeddah entered Newsweek's World's Best Specialized Hospitals 2027 ranking, compiled with Statista, for the first time, with five specialties recognized: nephrology, gastroenterology, pulmonology, urology and oncology. The hospital ranked first among all Saudi hospitals, public and private, in nephrology, gastroenterology and pulmonology, and first among private hospitals in urology. Nephrology placed 50th worldwide. The recognition builds on DSFH Jeddah's inclusion in Newsweek's World's Best Hospitals 2026 and its standing as the best private hospital in Saudi Arabia for five consecutive years. It reflects the depth of tertiary services behind the Group's case mix optimization toward complex care.

- **Advancing Complex and Robotic Care at DSFH Jeddah**
  DSFH Jeddah performed four consecutive robotic transoral thyroidectomies using the da Vinci system, the first in Saudi Arabia. The procedure removes the thyroid through the mouth, with no external neck incision. The hospital's thoracic team also completed a robotic Ivor Lewis esophagectomy for cancer at the gastroesophageal junction, a complex two-stage procedure, and the patient went home within a week. In orthopedics, the hospital carried out its first knee replacement assisted by the ROSA surgical robot, which adds real-time alignment data to its joint replacement program. Beyond the operating room, the Global Sepsis Alliance selected DSFH Jeddah as a Founding Pilot Partner. It joins a limited international group of hospitals that will test and validate a new global accreditation framework for sepsis care ahead of its launch in 1Q27.

- **Expansion Strategy Advancing Across Riyadh, Makkah and Jeddah**
  The Group consolidated Dr. Mohammed Al Fagih Hospital (DMFH) from July 2026 following completion of the acquisition, adding an established multispecialty hospital in Riyadh to its network. In Makkah, DSFMC Al Awali began receiving patients in 3Q26. It offers more than 20 clinics alongside 24-hour emergency, radiology, laboratory and pharmacy services, with a day surgery unit and a dialysis center planned. In Jeddah, DSFMC North Obhur opened in 4Q26 with more than 25 clinics, 24/7 emergency care and advanced imaging including MRI and CT, extending the Group's reach into the north of the city, and a day surgery and endoscopy unit will follow. DSFMC Al Zahra remains on track to open in 1Q27. Together, these medical centers widen the Group's catchment and direct complex cases to its hospitals. DSFMC Al Awali also builds the Group's presence in Makkah ahead of the planned DSFH Masar hospital.

Dr. Mohammed Al Fagih Hospital
Riyadh



DSFMC – Al Awali
Makkah




DSFMC – North Obhur
Jeddah




Total Operational Beds

(Beds/Occupancy %)




Total Patients Served

('000)




Outpatient Visits


('000)



Inpatient Admissions



Surgical Procedures



Operational Review

Fakeeh Care Group served 592,977 patients in 3Q26, up 24% from 3Q25, and 1,517,285 patients in 9M26, up 10% from 9M25. Much of this growth came from Dr. Mohammed Al Fagih Hospital (DMFH), which joined the Group in July 2026, while DSFH Riyadh and DSFH Madinah continued to ramp up. Complex care grew fastest. Inpatient admissions rose 54% to 20,209 in 3Q26 and 28% to 47,130 in 9M26, while surgical procedures rose 54% to 11,185 in 3Q26 and 34% to 25,633 in 9M26. On a like for like basis excluding DMFH, the same trend holds. In 3Q26, patients served grew 3% from 3Q25, while inpatient admissions grew 17% and surgical procedures 22%.

The Group ended 3Q26 with 763 operational beds, compared with 526 at the end of 3Q25. Group occupancy averaged 74% in 3Q26 (3Q25: 76%) as the newly added beds ramp up. More importantly, the Group has more than 340 built beds across DSFH Riyadh, DSFH Madinah and DMFH yet to be brought into operation. They can be commissioned without significant further capital expenditure, and the Group will bring them into service in step with demand, staffing and utilization. Their contribution to earnings will depend on how efficiently they are filled and run.


The Mature Business, comprising DSFH Jeddah, its medical centers (Medical Fakeeh, Basateen, Nuzha and the Executive clinic) and Home Healthcare, continued to raise the complexity of its case mix. Excluding Home Healthcare, average revenue per patient served rose 4% in 3Q26 and 3% in 9M26. This progress came in a more competitive Jeddah market, where the Mature Business served 6% fewer patients in both 3Q26 and 9M26, and inpatient occupancy eased from 86% in 3Q25 to above 80% in 3Q26. Management views this level as optimal for a busy tertiary hospital because it frees strategic capacity, enabling Mature Business surgeries to grow 3% in 9M26 despite serving fewer patients.

The New Business, comprising DSFH Riyadh, DSFH Madinah, DMFH, and DSFMC Al Awali as of 3Q26, served 208,673 patients in 3Q26, accounting for 35% of Group patients served, up from 14% in 3Q25. DSFH Riyadh ran at 81% occupancy on 103 operational beds in 3Q26, up from 71% on 103 beds in 3Q25, while inpatient admissions rose 46% and surgical procedures 82%. DSFH Madinah served over 39,000 patients in 3Q26, up 39% versus 2Q26. During 3Q26, the hospital expanded to 101 operational beds from 70, adding critical care capacity to meet strong demand in key complex specialties such as cardiology, oncology and orthopedics, which remain underserved in Madinah. Its occupancy still rose to 69% in 3Q26 from 59% in 2Q26.

DMFH brings an established multispecialty hospital to the network with 186 operational beds as of 3Q26, widens the Group's patient base in Riyadh, and holds the largest share of the Group's built capacity to be commissioned. In Makkah, DSFMC Al Awali began receiving patients in 3Q26, while in Jeddah DSFMC North Obhur began receiving patients in 4Q26 and will contribute to results from that quarter.

Financial Review

Group Revenue




Group revenue reached SAR 931 million in 3Q26, the highest quarterly revenue in the Group's history and 20% above 3Q25. Revenue for 9M26 rose 7% to SAR 2,454 million. Growth was led by the New Business, as DMFH joined the Group in July and DSFH Riyadh and DSFH Madinah continued to scale. Excluding DMFH, Group revenue grew 5% in 3Q26 and 2% in 9M26.

New Business revenue more than tripled to SAR 272 million in 3Q26 (3Q25: SAR 87 million) and rose 137% to SAR 510 million in 9M26. Excluding DMFH, New Business revenue grew 81% in 3Q26 and 84% in 9M26.


Mature Business revenue, which also includes the Group's O&M agreement, was SAR 562 million in 3Q26, down 11% from 3Q25, and SAR 1,702 million in 9M26, down 7% from 9M25. Around half of the decline reflects the optimization in the Group's O&M agreement. The rest reflects the more competitive Jeddah market and lower Home Healthcare revenue. The O&M agreement is priced on a cost plus basis, so its optimization reduced revenue with little effect on margin.

Ancillary businesses, which include education and technology as well as the Group's remaining supporting business lines, grew revenue 58% to SAR 97 million in 3Q26. In 9M26, ancillary revenue was SAR 243 million, in line with 9M25, despite prior year including a non-recurring Hajj contract.

Total Revenue Breakdown




Revenue Mix by Segment (% of Group revenue)




Together, these movements have changed the composition of Group revenue markedly. The New Business generated 29% of Group revenue in 3Q26 (3Q25: 11%), and its share has risen in every quarter over the past year. The Mature Business accounted for 60% (3Q25: 81%) and ancillary businesses for 10% (3Q25: 8%). In 9M26, the New Business generated 21% of Group revenue (9M25: 9%).

Healthcare Revenue Breakdown




The higher contribution from complex cases described in the Operational Review also carried through to revenue. Inpatient revenue grew 36% in 3Q26, against 22% for outpatient revenue. In 9M26, inpatient revenue grew 20% and outpatient revenue 11%. In the Mature Business, the same dynamic lifted average revenue per patient served by 4% in 3Q26 and 3% in 9M26 when excluding Home Healthcare patients.


Gross Profit
(SAR mn / Margin %)



Cost of Revenue Breakdown
(SAR mn / % of revenue)



New Business Gross Profit
(SAR mn / Margin %)



Operating Costs Analysis

Gross profit reached SAR 202 million in 3Q26, the highest quarterly gross profit in the Group's history and 14% above 3Q25. Gross profit for 9M26 was SAR 517 million, 3% below 9M25. The gross margin was 21.7% in 3Q26 (3Q25: 22.8%) and 21.1% in 9M26 (9M25: 23.3%).


Within cost of revenue, salaries and related benefits rose to 42.4% of revenue in 3Q26 (3Q25: 40.2%) and 41.9% in 9M26 (9M25: 41.2%). The Group staffed new capacity ahead of its ramp up, including DSFMC Al Awali, which began receiving patients in 3Q26, and DSFMC North Obhur ahead of its opening in 4Q26. A competitive market for clinical talent also added to attraction and retention costs. Materials and consumables rose to 24.1% of revenue in 3Q26 (3Q25: 23.5%) and 24.3% in 9M26 (9M25: 22.9%), reflecting regional supply chain pressures on costs and prices. Other costs of revenue fell to 11.8% of revenue in 3Q26 (3Q25: 13.5%) and were broadly stable at 12.8% in 9M26 (9M25: 12.6%), supported by the Group's cost containment, avoidance and reduction initiatives.

The New Business turned a gross loss of SAR 20 million in 3Q25 into a gross profit of SAR 34 million in 3Q26, and a gross loss of SAR 50 million in 9M25 into a gross profit of SAR 22 million in 9M26. In 3Q26, DSFH Riyadh and DSFH Madinah generated a combined gross profit more than enough to absorb the opening costs of DSFMC Al Awali and DSFMC North Obhur. The New Business therefore remained profitable at gross level even before the contribution of DMFH, which joined in July. This marks a turning point, as the segment can now absorb new additions to the network and still contribute positively.


The Mature Business and ancillary businesses contributed less gross profit than a year earlier, reflecting the optimization in the Group's O&M agreement, lower Home Healthcare revenue, and fewer patients in a more competitive Jeddah market against a cost base that is largely fixed in the short term. Their gross margin eased to 25.5% in 3Q26 and 25.4% in 9M26, but remained well above the Group average, supported by a higher contribution from complex cases.

At Group level, the improvement in the New Business more than offset the lower contribution from the Mature Business and ancillary businesses in 3Q26, lifting gross profit by 14%, while in 9M26 it offset most of that lower contribution. The lower Group margin also reflects mix, as the New Business now accounts for 29% of Group revenue (3Q25: 11%). The Mature Business and ancillary businesses still earn margins well above the Group average, while the New Business is still ramping up at lower margins. As the New Business margin builds with higher utilization, that growing weight should support the Group's margin.


SG&A
(SAR mn / SG&A to Revenue %)




EBITDA
(SAR mn / Margin %)



Net Profit
(SAR mn / Margin %)



Attributable Net Profit
(SAR mn)



Operating Profitability analysis

Group EBITDA reached SAR 138 million in 3Q26, 10% above 3Q25. EBITDA for 9M26 was SAR 357 million, 5% below 9M25. The EBITDA margin was 14.8% in 3Q26 (3Q25: 16.1%) and 14.5% in 9M26 (9M25: 16.4%).

Selling, general and administrative (SG&A) expenses rose to SAR 125 million in 3Q26 (3Q25: SAR 99 million), or 13.4% of revenue (3Q25: 12.8%), and to 12.9% of revenue in 9M26 (9M25: 12.5%). Almost all of the increase came from the New Business as the Group consolidated DMFH, opened DSFMC Al Awali and prepared DSFMC North Obhur. Across the rest of the Group, SG&A expenses were held flat in both 3Q26 and 9M26 versus prior year periods. New facilities carry their full overhead before their revenue builds, so this ratio rises when they join and eases as they scale.

As in gross profit, the New Business recorded positive EBITDA for the first time, at SAR 6 million in 3Q26 compared with a loss of SAR 30 million in 3Q25. For 9M26, its EBITDA loss narrowed by 63% to SAR 34 million (9M25: SAR 93 million). The improvement at DSFH Riyadh and DSFH Madinah, along with the positive contribution from DMFH from July, more than offset the opening costs of DSFMC Al Awali and DSFMC North Obhur.

The Mature Business and ancillary businesses held a stable EBITDA margin of around 20% in each quarter of 2026. Their lower contribution year on year reflects the same factors that shaped gross profit. Home Healthcare weighed far more than its small share of revenue suggests, given its fixed cost base, and remains a focus for management. SG&A in these businesses was held relatively flat in 3Q26 and 9M26, supported by the Group's centralization, outsourcing and cost containment initiatives, which limited the impact.

At Group level, the SAR 36 million improvement in the New Business EBITDA more than offset the lower contribution from the Mature Business and ancillary businesses in 3Q26, lifting Group EBITDA by 10% compared to 3Q25. The lower Group EBITDA margin also reflects the growing weight of the New Business while its margin builds.

Net Profit

Although EBITDA grew 10% in 3Q26 from 3Q25, as improved New Business profitability, including the contribution from DMFH, more than offset a decline in the Mature Business, the additional depreciation and financing costs of the DMFH acquisition reduced net profit to SAR 38 million in 3Q26 (3Q25: SAR 57 million) and SAR 118 million in 9M26 (9M25: SAR 193 million). Both are largely fixed costs of the capacity the Group has put in place, so their weight on earnings depends on how quickly and efficiently that capacity is utilized.


Depreciation and amortization rose to SAR 66 million in 3Q26 (3Q25: SAR 49 million) and SAR 168 million in 9M26 (9M25: SAR 137 million). DMFH accounted for around half of the 3Q26 increase, while the

expanded capacity at DSFH Madinah drove most of the remaining increase in 9M26. Net finance costs rose to SAR 28 million in 3Q26 (3Q25: SAR 9 million) and SAR 48 million in 9M26 (9M25: SAR 16 million), reflecting both the financing of the DMFH acquisition and its own debt.

Profit attributable to shareholders declined more than net profit in 3Q26 because DSFH Riyadh and DSFH Madinah are partly owned, and minority partners share in their improved results. As a result, losses attributable to non-controlling interests fell to SAR 1 million in 3Q26 (3Q25: SAR 15 million) and SAR 17 million in 9M26 (9M25: SAR 33 million).

Balance Sheet, Liquidity & Capital Deployment


The Group ended 3Q26 with total liquid funds of SAR 737 million, comprising SAR 436 million in cash and SAR 300 million in government sukuk. This restored liquidity to its December 2025 level, up from SAR 657 million in June 2026.



Cash as of Dec 2025 & Sep 2026 include Sukuk amounting to SAR 298.1mn & SAR 300.3mn respectively

During 3Q26, the Group completed the acquisition of DMFH for a total cash consideration of SAR 1.6 billion. Alongside the acquisition, capex and investments amounted to SAR 301 million in 9M26. The Group brought DSFMC Al Awali into operation in 3Q26 and DSFMC North Obhur in 4Q26, and DSFMC Al Zahra remains on track for completion in 1Q27.

The Group consolidated DMFH's assets and liabilities from July 2026. In line with IFRS 3, the Group recognized, on a provisional basis, goodwill and intangibles of SAR 1,042 million on the acquisition, which lifted intangible assets and goodwill to SAR 1,587 million (December 2025: SAR 548 million).



The acquisition was funded through credit facilities secured from local banks, with no new shares issued. Following the financing of the DMFH acquisition and its consolidation, total debt stood at SAR 2,977 million (December 2025: SAR 632 million). Net debt, including government sukuk, was SAR 2,241 million, compared with a net cash position of SAR 106 million at December 2025. This represents 0.61 times total equity, which rose to SAR 3,649 million (December 2025: a net cash position equal to 0.03 times equity of SAR 3,581 million). Net debt to LTM EBITDA reads 4.1 times (December 2025: a net cash position equal to 0.2 times EBITDA).[1] The Group expects leverage to decline as EBITDA grows with the ramp up of its built capacity, supported by the cash flows of its hospitals, including DMFH.

[1] *Pro forma LTM EBITDA adds DMFH's EBITDA for October 2025 to June 2026, the period before it was consolidated, based on its management accounts and excluding one-off adjustments recorded in June 2026 ahead of completion.*

Management Priorities

With its expansion largely in place, the Group's priority is to convert its larger platform into sustainable profitability and cash generation.

In the Mature Business, the Group is protecting performance through a higher contribution from complex cases, a shorter average length of stay and greater automation, which lift bed turnover and revenue per bed on the same patient footfall. Its growing network of medical centers, including DSFMC North Obhur and DSFMC Al Zahra, widens its catchment and routes more complex cases into DSFH Jeddah. Home Healthcare remains a focus for management.

In the New Business, DSFH Riyadh and DSFH Madinah are now EBITDA positive, and DMFH adds an established hospital with positive EBITDA. As the New Business grows, it is expected to offset pressure elsewhere in the Group and to cover more of the depreciation and financing costs that came with the expansion, allowing more of its growth to reach net profit. The remaining built beds will be commissioned in step with demand, staffing and utilization.

Across the Group, management continues to centralize support functions, outsource services and contain costs, and is bringing DMFH onto the Group's procurement and shared services platform. Capital will be deployed selectively, with each investment assessed on its return.

– Ends –

About Fakeeh Care Group

Established in 1978 by the late Dr. Soliman Fakeeh, the Fakeeh Care Group stands as a pioneer in integrated healthcare services in Saudi Arabia. Our comprehensive healthcare offering includes our core healthcare services ranging from ambulatory care to secondary and tertiary care, supported by Emergency Medical Services and Fakeeh Home Healthcare. Additionally, our offerings are enhanced by our industry-leading academic healthcare programs. Building on a strong track record of growth in our home city of Jeddah, the Group embarked on a Kingdom-wide expansion strategy to bring our well proven hub-and-spoke model and medical support services to major cities across Saudi Arabia.

As at 30 September 2026, the Group operates four hospitals with 763 operational beds within a total built capacity of 1,135 beds: DSFH Jeddah (373 of 400 beds), DSFH Riyadh (103 of 185), Dr. Mohammed Al Fagih Hospital in Riyadh (186 of 350) and DSFH Madinah (101 of 200). These are complemented by five medical centers: Medical Fakeeh, DSFMC Basateen, DSFMC Nuzha and DSFMC Executive in Jeddah, and DSFMC Al Awali in Makkah. The Group also operates a hospital and a medical center on behalf of third parties under operate and manage agreements.

For further information, please contact:

Mr Waleed Hamed
Investments & Investor Relations Director
Email: wahamed@fakeeh.care

Mr Panagiotis (Panos) Chatziantoniou
Vice President, Group Investments and Treasury
Email: investors@fakeeh.care

Forward-looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as “according to estimates”, “anticipates”, “assumes”, “believes”, “could”, “estimates”, “expects”, “intends”, “is of the opinion”, “may”, “plans”, “potential”, “predicts”, “projects”, “should”, “to the knowledge of”, “will”, “would”, or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding the Company’s business and management, its future growth or profitability and general economic and regulatory conditions and other matters affecting it.

These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and its investments, including, among other things, the development of its business, financial condition, prospects, growth, strategies, as well as the trends in the industry and macroeconomic developments in the Kingdom of Saudi Arabia. Many of these risks and uncertainties relate to factors that are beyond the Company's control or accurate estimation, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and any changes in applicable laws or regulations or government policies. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not otherwise occur and past performance shall not be taken as a guarantee of future results. No representation or warranty is made pertaining to any forward-looking statement made by the Company. The Company does not intend to update, supplement, amend or revise any such forward-looking statement whether as a result of new information, future events or otherwise. Nothing in the Information shall be construed as a profit forecast.

The Information may include financial information that are not defined or recognized under the International Financial Reporting Standards (IFRS). These measures are derived from the Company’s consolidated financial statements and provided as additional information to complement IFRS measures. Any financial information provided by the Company should not be considered in isolation or as a substitute for analysis of the Company’s financial information as reported under the IFRS.

Consolidated Income Statement

SAR millions	3Q-2026	3Q-2025	YoY %	9M-2026	9M-2025	YoY %
Revenue	931.3	778.3	19.7%	2,454.3	2,291.1	7.1%
Costs of revenue	(729.4)	(601.0)	21.4%	(1,937.6)	(1,757.1)	10.3%
Gross profit	**201.9**	**177.2**	**13.9%**	**516.8**	**534.0**	**-3.2%**
Gross profit margin	***21.7%***	***22.8%***	***-1.1pp***	***21.1%***	***23.3%***	***-2.3pp***
Other income	4.1	3.9	6.2%	11.1	10.9	2.3%
General and administrative expenses	(103.0)	(78.7)	30.9%	(256.1)	(229.6)	11.5%
Selling and marketing expenses	(22.1)	(20.6)	7.1%	(61.1)	(57.6)	6.0%
Long-term Incentive Plan	(1.2)	(1.9)	-38.1%	(3.5)	(5.7)	-38.1%
Impairment loss on receivables	(9.3)	(5.8)	61.2%	(22.4)	(19.2)	16.4%
Operating profit	**70.4**	**74.1**	**-5.0%**	**184.8**	**232.7**	**-20.6%**
Operating Profit margin	***7.6%***	***9.5%***	***-2.0pp***	***7.5%***	***10.2%***	***-2.6pp***
Finance cost	(35.5)	(14.1)	151.4%	(69.1)	(34.0)	103.1%
Finance income	7.2	4.7	52.5%	20.6	17.9	15.6%
Share of profit of associate	0.1	-	n/m	0.1	-	n/m
Profit before Zakat	**42.3**	**64.8**	**-34.7%**	**136.4**	**216.5**	**-37.0%**
Zakat	(4.4)	(7.6)	-43.0%	(18.1)	(23.9)	-24.2%
Profit after Zakat	**37.9**	**57.1**	**-33.6%**	**118.2**	**192.6**	**-38.6%**
Profit margin	***4.1%***	***7.3%***	***-3.3pp***	***4.8%***	***8.4%***	***-3.6pp***
Profit for the period attributable to:						
Shareholders of the Company	**38.7**	**71.6**	**-45.9%**	**135.1**	**226.0**	**-40.2%**
Non-controlling interest	(0.8)	(14.5)	-94.4%	(16.9)	(33.3)	-49.4%
Additional information:						
EPS[1]	0.17	0.31	-45.9%	0.59	0.98	-40.2%
EBITDA	**137.6**	**125.0**	**10.1%**	**356.8**	**375.3**	**-4.9%**
EBITDA margin	***14.8%***	***16.1%***	***-1.3pp***	***14.5%***	***16.4%***	***-1.8pp***

[1] *Earnings per share (EPS) is calculated based on attributable net profit and the weighted average number of shares which reads 230,000,000 shares as of 9M26, and 230,000,000 as of 9M25.*

Consolidated Balance Sheet

SAR millions	30-Sep-26	31-Dec-25
ASSETS		
Property and equipment	3,644.1	2,498.8
Right-of-use assets	591.8	492.2
Intangible assets and goodwill	1,587.3	547.6
Investment properties	0.3	0.4
Investments in associate	70.1	-
Financial asset at amortized cost	-	298.1
Prepayments and other non-current assets	24.0	22.2
Other long-term receivables	136.0	144.7
Non-current assets	**6,053.5**	**4,004.1**
Inventories	224.6	196.3
Accounts and other receivables	1,228.4	975.0
Contract assets	45.0	39.8
Prepayments and other current assets	191.1	174.4
Financial asset at amortized cost – current portion	300.3	-
Cash and cash equivalents	436.4	439.2
Current assets	**2,425.8**	**1,824.6**
TOTAL ASSETS	**8,479.3**	**5,828.7**
EQUITY		
Share capital	232.0	232.0
Treasury shares	(2.0)	(2.0)
Share premium	1,653.5	1,653.5
Profit/loss for the period	135.1	290.2
Retained earnings	1,216.2	998.4
Equity attributable to shareholders of the Company	**3,234.7**	**3,172.0**
Non-controlling interests	413.9	409.4
Total equity	**3,648.6**	**3,581.4**
LIABILITIES		
Long-term loans	2,324.5	334.0
Lease liabilities	573.6	481.2
Employees' end of service benefits	348.0	313.0
Non-current liabilities	**3,246.0**	**1,128.2**
Short-term loans	609.0	297.5
Current portion of long-term loans	43.7	-
Current portion of lease liabilities	80.9	63.7
Accounts payables	373.7	362.2
Accrued and other current liabilities	459.6	365.4
Accrued Zakat	17.8	30.3
Current liabilities	**1,584.6**	**1,119.1**
Total liabilities	**4,830.6**	**2,247.3**
TOTAL EQUITY AND LIABILITIES	**8,479.3**	**5,828.7**